11596

531633

LINCOLN

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

LINCOLN PHARMA LTD Share Price Today

LINCOLN PHARMA LTD is currently trading at ₹628.35, down by ₹4.95 from the previous close. The stock touched an intraday high of ₹637.45 and a low of ₹625.00 during the latest trading session. Over the past one year, LINCOLN PHARMA LTD has delivered a return of 7.11%, while the stock has declined 8.16% in the last one month.

LINCOLN PHARMA LTD performance

Today’s low Today’s high
₹ 625.00 ₹ 637.45
₹ 628.55
52 week low 52 week high
₹ 440.00 ₹ 770.00
₹ 628.55
Open Price ₹ 633.00
Prev. Close ₹ 633.30
Volume (Shares) 9488.00
Total traded value ₹ 59.63
Upper Circuit ₹ 759.95
Lower Circuit ₹ 506.65
info

Investment Returns

Over 1 Month -8.16% Over 3 Months 0.51% Over 6 Months 28.37% Over 1 Year 7.11%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

LINCOLN PHARMA LTD fundamentals


  • Market cap (Cr) 1,259.00
  • P/E Ratio (TTM) 14.45
  • Beta 0.62
  • Book Value / share 378.25
  • Return on equity 13.02%
  • EPS (TTM) 43.88
  • Dividend yield 0.28%
  • Net profit/quarter (Cr) 11.63
info icon alternate text
  • Market cap (Cr) 1,262.80
  • P/E Ratio (TTM) 14.45
  • Beta 0.53
  • Book Value / share 378.25
  • Return on equity 13.02%
  • EPS (TTM) 43.88
  • Dividend yield 0.28%
  • Net profit/quarter (Cr) 11.63
info icon alternate text

LINCOLN PHARMA LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 187.28
Operating Expense 166.38
Net Profit 11.63
Net Profit Margin (%) 6.20
Earnings Per Share (EPS) 5.81
EBITDA 20.65
Effective Tax Rate (%) 30.35
Particulars DEC 2025 (Values in Cr)
Revenue 166.32
Operating Expense 146.75
Net Profit 28.60
Net Profit Margin (%) 17.19
Earnings Per Share (EPS) 14.28
EBITDA 38.73
Effective Tax Rate (%) 17.62
Particulars SEP 2025 (Values in Cr)
Revenue 163.36
Operating Expense 141.78
Net Profit 19.98
Net Profit Margin (%) 12.23
Earnings Per Share (EPS) 9.98
EBITDA 32.66
Effective Tax Rate (%) 30.64
Particulars JUN 2025 (Values in Cr)
Revenue 154.07
Operating Expense 133.95
Net Profit 27.68
Net Profit Margin (%) 17.96
Earnings Per Share (EPS) 13.82
EBITDA 39.08
Effective Tax Rate (%) 21.78
Particulars MAR 2025 (Values in Cr)
Revenue 168.18
Operating Expense 145.06
Net Profit 11.58
Net Profit Margin (%) 6.88
Earnings Per Share (EPS) 5.78
EBITDA 19.85
Effective Tax Rate (%) 28.73
Particulars MAR 2026 (Values in Cr)
Revenue 671.03
Operating Expense 588.86
Net Profit 87.89
Net Profit Margin (%) 13.09
Earnings Per Share (EPS) 43.88
EBITDA 131.14
Effective Tax Rate (%) 23.98
Particulars MAR 2025 (Values in Cr)
Revenue 623.23
Operating Expense 536.52
Net Profit 82.35
Net Profit Margin (%) 13.21
Earnings Per Share (EPS) 41.11
EBITDA 123.97
Effective Tax Rate (%) 24.58
Particulars MAR 2024 (Values in Cr)
Revenue 580.55
Operating Expense 492.72
Net Profit 93.30
Net Profit Margin (%) 16.07
Earnings Per Share (EPS) 46.58
EBITDA 134.32
Effective Tax Rate (%) 23.67
Particulars MAR 2023 (Values in Cr)
Revenue 510.31
Operating Expense 432.34
Net Profit 72.90
Net Profit Margin (%) 14.28
Earnings Per Share (EPS) 36.40
EBITDA 111.66
Effective Tax Rate (%) 27.43
Particulars MAR 2022 (Values in Cr)
Revenue 472.08
Operating Expense 386.15
Net Profit 69.36
Net Profit Margin (%) 14.69
Earnings Per Share (EPS) 34.63
EBITDA 105.47
Effective Tax Rate (%) 27.69
Particulars MAR 2025 (Values in Cr)
Book Value / Share 335.34
ROE % 13.02
ROCE % 17.42
Total Debt to Total Equity 0.00
EBITDA Margin 19.89
Particulars MAR 2024 (Values in Cr)
Book Value / Share 295.98
ROE % 17.04
ROCE % 22.35
Total Debt to Total Equity 0.00
EBITDA Margin 23.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 250.86
ROE % 15.59
ROCE % 21.61
Total Debt to Total Equity 0.00
EBITDA Margin 21.88
Particulars MAR 2022 (Values in Cr)
Book Value / Share 216.12
ROE % 17.36
ROCE % 24.03
Total Debt to Total Equity 0.00
EBITDA Margin 22.34
Particulars MAR 2021 (Values in Cr)
Book Value / Share 182.92
ROE % 18.32
ROCE % 24.60
Total Debt to Total Equity 0.01
EBITDA Margin 21.89
Particulars MAR 2025 (Values in Cr)
Book Value / Share 335.34
ROE % 13.02
ROCE % 17.42
Total Debt to Total Equity 0.00
EBITDA Margin 19.89
Particulars MAR 2024 (Values in Cr)
Book Value / Share 295.98
ROE % 17.04
ROCE % 22.35
Total Debt to Total Equity 0.00
EBITDA Margin 23.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 250.86
ROE % 15.59
ROCE % 21.60
Total Debt to Total Equity 0.00
EBITDA Margin 21.88
Particulars MAR 2022 (Values in Cr)
Book Value / Share 216.12
ROE % 17.35
ROCE % 24.02
Total Debt to Total Equity 0.00
EBITDA Margin 22.34
Particulars MAR 2021 (Values in Cr)
Book Value / Share 182.92
ROE % 18.56
ROCE % 24.90
Total Debt to Total Equity 0.01
EBITDA Margin 21.94
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 22.43
Total Assets 797.00
Total Liabilities 797.00
Total Equity 671.66
Share Outstanding 2
Price to Book Ratio 1.64
Return on Assets (%) 10.33
Return on Capital (%) 12.26
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.83
Total Assets 700.29
Total Liabilities 700.29
Total Equity 592.83
Share Outstanding 2
Price to Book Ratio 1.98
Return on Assets (%) 13.32
Return on Capital (%) 15.71
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 34.31
Total Assets 587.42
Total Liabilities 587.42
Total Equity 502.47
Share Outstanding 2
Price to Book Ratio 1.35
Return on Assets (%) 12.41
Return on Capital (%) 14.45
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 18.79
Total Assets 534.35
Total Liabilities 534.35
Total Equity 432.87
Share Outstanding 2
Price to Book Ratio 1.44
Return on Assets (%) 12.97
Return on Capital (%) 15.95
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 13.84
Total Assets 452.35
Total Liabilities 452.35
Total Equity 366.39
Share Outstanding 2
Price to Book Ratio 1.23
Return on Assets (%) 13.76
Return on Capital (%) 16.97
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 21.99
Total Assets 796.86
Total Liabilities 796.86
Total Equity 671.66
Share Outstanding 2
Price to Book Ratio 1.64
Return on Assets (%) 10.33
Return on Capital (%) 12.26
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 13.38
Total Assets 700.14
Total Liabilities 700.14
Total Equity 592.83
Share Outstanding 2
Price to Book Ratio 1.98
Return on Assets (%) 13.32
Return on Capital (%) 15.71
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 33.84
Total Assets 587.25
Total Liabilities 587.25
Total Equity 502.47
Share Outstanding 2
Price to Book Ratio 1.35
Return on Assets (%) 12.41
Return on Capital (%) 14.45
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 18.43
Total Assets 534.11
Total Liabilities 534.11
Total Equity 432.87
Share Outstanding 2
Price to Book Ratio 1.44
Return on Assets (%) 12.98
Return on Capital (%) 15.95
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 13.43
Total Assets 451.80
Total Liabilities 451.80
Total Equity 366.39
Share Outstanding 2
Price to Book Ratio 1.23
Return on Assets (%) 13.77
Return on Capital (%) 16.97
Particulars MAR 2025 (Values in Cr)
Net Income 109.18
Cash from Operations 119.32
Cash from Investing -78.94
Cash from Financing -6.40
Net change in Cash 7.66
Free Cash Flow 138.35
Particulars MAR 2024 (Values in Cr)
Net Income 122.24
Cash from Operations 89.36
Cash from Investing -57.34
Cash from Financing -5.18
Net change in Cash 0.69
Free Cash Flow 128.84
Particulars MAR 2023 (Values in Cr)
Net Income 100.47
Cash from Operations 68.87
Cash from Investing -36.64
Cash from Financing -4.50
Net change in Cash -1.88
Free Cash Flow 83.13
Particulars MAR 2022 (Values in Cr)
Net Income 95.93
Cash from Operations 99.82
Cash from Investing -78.08
Cash from Financing -2.55
Net change in Cash -4.50
Free Cash Flow 145.35
Particulars MAR 2021 (Values in Cr)
Net Income 83.72
Cash from Operations 88.76
Cash from Investing -64.22
Cash from Financing -5.74
Net change in Cash -0.70
Free Cash Flow 97.51
Particulars MAR 2025 (Values in Cr)
Net Income 109.18
Cash from Operations 119.32
Cash from Investing -78.94
Cash from Financing -6.40
Net change in Cash 7.66
Free Cash Flow 138.35
Particulars MAR 2024 (Values in Cr)
Net Income 122.24
Cash from Operations 89.37
Cash from Investing -57.34
Cash from Financing -5.17
Net change in Cash 0.72
Free Cash Flow 128.84
Particulars MAR 2023 (Values in Cr)
Net Income 100.45
Cash from Operations 68.76
Cash from Investing -36.64
Cash from Financing -4.50
Net change in Cash -1.98
Free Cash Flow 83.02
Particulars MAR 2022 (Values in Cr)
Net Income 95.92
Cash from Operations 99.82
Cash from Investing -78.08
Cash from Financing -2.56
Net change in Cash -4.46
Free Cash Flow 145.34
Particulars MAR 2021 (Values in Cr)
Net Income 83.67
Cash from Operations 88.84
Cash from Investing -64.39
Cash from Financing -5.73
Net change in Cash -0.74
Free Cash Flow 97.59
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.24 14.15 1.65 262.39 23.12 38.85
BLISS GVS PHARMA LTD 419.15 33.91 3.71 4434.14 118.35 462.70
CIPLA LTD 1388.25 29.46 3.25 112149.13 1165.55 1672.20
FERMENTA BIOTECH LTD. 341.00 15.04 2.46 1003.60 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 34.24 23.94 4.41 262.39 23.12 38.85
AMRUTANJAN HEALTH CARE LTD. 554.85 24.87 4.33 1604.11 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8383.40 109.49 24.01 20958.50 7630.00 10653.05
BLISS GVS PHARMA LTD 419.15 45.07 3.83 4434.14 118.35 462.70

LINCOLN PHARMA LTD shareholding pattern

Holding
43.94%
49.77%
5.19%
1.08%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

LINCOLN PHARMA LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
628.55 -0.75 redarrow
red-green-graph indicator
11 Bearish
5 Bullish
  • 5 Days 629.60
  • 26 Days 649.30
  • 10 Days 637.90
  • 50 Days 637.40
  • 12 Days 641.40
  • 100 Days 608.20
  • 20 Days 648.80
  • 200 Days 587.10
626.72 PIVOT
First Support 609.43 First Resistance 637.08 Second Support 599.07 Second Resistance 654.37 Third Support 581.78 Third Resistance 664.73
RSI 43.96 ADX 28.46 MACD -7.80 Williams % R -81.23 Commodity Channel Index (CCI) -73.73
Date 2026-06-08 Week 65008.00 Same Day 29473.00 Month 62443.00
1 Year 0.62 3 Year 0.86
Over 1 Month
-8.16% down
Over 1 Year
7.11% down
Over 3 Months
0.51% down
Over 3 Years
18.05% down
Over 6 Months
28.37% down
Over 5 Years
16.21% down

LINCOLN PHARMA LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
12 Sep 2025 1.8 Final 12 Sep 2025 Equity shares
13 Sep 2024 1.8 Final 14 Sep 2024 Equity shares
15 Sep 2023 1.5 Final 16 Sep 2023 Equity shares
15 Sep 2022 1.5 Final 17 Sep 2022 Equity shares
16 Sep 2021 1.5 Final 18 Sep 2021 Equity shares
05 Mar 2020 1.5 Interim 06 Mar 2020 Equity shares
19 Sep 2019 1.5 Final 21 Sep 2019 Equity shares
19 Sep 2018 1.5 Final 22 Sep 2018 Equity shares
21 Sep 2017 1.2 Final 23 Sep 2017 Equity shares
23 Sep 2016 1.0 Final 27 Sep 2016 Equity shares
23 Sep 2015 1.0 Final 26 Sep 2015 Equity shares
25 Sep 2014 0.6 Final 27 Sep 2014 Equity shares
19 Sep 2013 0.6 Final 21 Sep 2013 Equity shares
20 Sep 2012 0.6 Final 22 Sep 2012 Equity shares
22 Sep 2011 0.6 Final 24 Sep 2011 Equity shares
23 Sep 2010 1.2 Final 25 Sep 2010 Equity shares
17 Sep 2009 1.2 Final 19 Sep 2009 Equity shares
18 Sep 2008 0.24 Final 20 Sep 2008 Equity shares
20 Sep 2007 0.24 Final 22 Sep 2007 Equity shares
14 Sep 2006 0.0 Final 16 Sep 2006 Equity shares
25 Aug 2005 0.0 Final 29 Aug 2005 Equity shares
Ex-Date Old FV NEW FV Record Date
19 Mar 2009 2.0 10.0 26 Mar 2009
08 Feb 2006 10.0 2.0 16 Feb 2006
Dividend date Dividend amount Dividend type Record date Instrument type
12 Sep 2025 1.8 Final 12 Sep 2025 Equity shares
13 Sep 2024 1.8 Final 14 Sep 2024 Equity shares
15 Sep 2023 1.5 Final 16 Sep 2023 Equity shares
15 Sep 2022 1.5 Final 17 Sep 2022 Equity shares
16 Sep 2021 1.5 Final 18 Sep 2021 Equity shares
05 Mar 2020 1.5 Interim 06 Mar 2020 Equity shares
19 Sep 2019 1.5 Final 21 Sep 2019 Equity shares
19 Sep 2018 1.5 Final 22 Sep 2018 Equity shares
21 Sep 2017 1.2 Final 23 Sep 2017 Equity shares
23 Sep 2016 1.0 Final 27 Sep 2016 Equity shares
23 Sep 2015 1.0 Final 26 Sep 2015 Equity shares
25 Sep 2014 0.6 Final 27 Sep 2014 Equity shares
19 Sep 2013 0.6 Final 21 Sep 2013 Equity shares
20 Sep 2012 0.6 Final 22 Sep 2012 Equity shares
22 Sep 2011 0.6 Final 24 Sep 2011 Equity shares
23 Sep 2010 1.2 Final 25 Sep 2010 Equity shares
17 Sep 2009 1.2 Final 19 Sep 2009 Equity shares
18 Sep 2008 0.24 Final 20 Sep 2008 Equity shares
20 Sep 2007 0.24 Final 22 Sep 2007 Equity shares
14 Sep 2006 0.0 Final 16 Sep 2006 Equity shares
25 Aug 2005 0.0 Final 29 Aug 2005 Equity shares
Ex-Date Old FV NEW FV Record Date
19 Mar 2009 2.0 10.0 26 Mar 2009
08 Feb 2006 10.0 2.0 16 Feb 2006

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Lincoln Pharmaceuticals Ltd?

Answer Field

Lincoln Pharmaceuticals Ltd share price is for NSE ₹ 628.35 & for BSE ₹ 626.90 as on Jun 11 2026 02:10 PM.

What is the Market Cap of Lincoln Pharmaceuticals Ltd Share?

Answer Field

The market cap of Lincoln Pharmaceuticals Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 11 2026 02:10 PM.

What is the 52 Week High and Low of Lincoln Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Lincoln Pharmaceuticals Ltd for NSE is ₹ 770.00 and ₹ 440.00 and for BSE is ₹ 770.00 and ₹ 439.95.

What is 1 year return for Lincoln Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 9.46%.

What is the P/E Ratio of Lincoln Pharmaceuticals Ltd Share?

Answer Field

As on Jun 11 2026 02:10 PM the price-to-earnings (PE) ratio for Lincoln Pharmaceuticals Ltd share is 14.45.

What is the PB ratio of Lincoln Pharmaceuticals Ltd Share?

Answer Field

As on Jun 11 2026 02:10 PM, the price-to-book (PB) ratio for Lincoln Pharmaceuticals Ltd share is 378.25.

How to Buy Lincoln Pharmaceuticals Ltd Share?

Answer Field

You can trade in Lincoln Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Lincoln Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Lincoln Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Lincoln Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|